Revolution Medicines (RVMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Revolution Medicines

NasdaqGS•Healthcare•Biotechnology

$210.02-0.85(<0.01%)Pre-market

Market Cap

$41.53B

P/B

15.9x

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

How this company scores

WeakMetricSide Score: 23/100

Grade capped at D — Interest coverage below 1× (-17.1x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (7/25); weakest: Profitability (4/25).

Profitability4/25

Growth6/25

Balance Sheet & Red Flags7/25

Cash & Earnings Quality6/25

Strengths

Net cash position

Grade capped at D

Interest coverage below 1× (-17.1x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1657.1x5y range 52.0x – 1657.1x

Currently above its 9-quarter median.

P/B · 15.9x5y range 1.8x – 15.9x

Currently above its 16-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $41.53B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-1.61B
TTM Op. Income: $-1.63B
Q. Op. Income: $-505.13M
TTM Net Income: $-1.77B
Q. Net Income: $-644.37M
EPS: $-3.06
Shares Out.: $210.89M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-1.61B and TTM operating income of $-1.63B show growth is flowing through to the bottom line. However, net income is negative at $1.77B — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -50513200000.0%
Net Margin: -64437100000.0%

Op. margin of -50513200000.0% is down 24041800000.0% YoY — costs are rising relative to revenue. Net margin at -64437100000.0% Across the last 8 quarters, operating margin has fallen for 7 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 15.9x

P/S of 0.0x and P/B of 15.9x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $4.32B
Cash: $815.43M
Long-Term Debt: N/A
Book Value: $2.61B
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-387.32M
TTM Free Cash Flow: $-1.23B
FCF Margin: N/A
FCF / Net Income: 0.7

TTM FCF of $-1.23B on $-387.32M in operating cash flow. The FCF / Net Income ratio of 0.7x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 7 consecutive quarters — a weakening trend.